M-CSF-specific monoclonal antibody and uses thereof
US8652469B2 · kind B2 · utility
5Cited by
53References
13Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 27, 2006 |
| Grant date | Feb 18, 2014 |
| Priority date | — |
| Expiry date | Apr 21, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
M-CSF-specific RX1-based or RX-I derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in or remodeling in a subject afflicted with an osteoblastic or osteolytic disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.